Raynaud's syndrome.
作者信息
Cooke E D, Nicolaides A N
机构信息
Department of Medical Electronics, St Bartholomew's Hospital, London.
出版信息
BMJ. 1990 Mar 3;300(6724):553-5. doi: 10.1136/bmj.300.6724.553.
Abstract
摘要
相似文献
1
Raynaud's syndrome.
BMJ. 1990 Mar 3;300(6724):553-5. doi: 10.1136/bmj.300.6724.553.
2
Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.
BMJ. 1989 Mar 4;298(6673):561-4. doi: 10.1136/bmj.298.6673.561.
3
Successful treatment of Raynaud's syndrome with Iloprost, a chemically stable prostacyclin analogue.
Br J Rheumatol. 1988 Jun;27(3):220-6. doi: 10.1093/rheumatology/27.3.220.
4
[Effect of a-sympathicolysis in Raynaud's syndrome].
Verh Dtsch Ges Inn Med. 1973;79:1395-7.
5
Retrospective comparison of iloprost with other treatments for secondary Raynaud's phenomenon.
Ann Rheum Dis. 1991 Jun;50(6):359-61. doi: 10.1136/ard.50.6.359.
6
Raynaud's syndrome.
BMJ. 1990 Apr 14;300(6730):1015-6. doi: 10.1136/bmj.300.6730.1015-b.
7
Prolonged increase in digital blood flow following iloprost infusion in patients with systemic sclerosis.
Postgrad Med J. 1987 Aug;63(742):617-20. doi: 10.1136/pgmj.63.742.617.
8
Renin-angiotensin system mediators and Raynaud's phenomenon.
Ann Pharmacother. 2006 Nov;40(11):1998-2002. doi: 10.1345/aph.1H201. Epub 2006 Sep 26.
9
Raynaud's disease.
Arch Dis Child. 1985 Jun;60(6):537-41. doi: 10.1136/adc.60.6.537.
10
Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study.
Clin Exp Rheumatol. 2001 Sep-Oct;19(5):503-8.
引用本文的文献
1
Increased capillary permeability in systemic sclerosis: help or hindrance?
Ann Rheum Dis. 1996 Sep;55(9):603-6. doi: 10.1136/ard.55.9.603.
2
Raynaud's syndrome.
BMJ. 1990 Apr 28;300(6732):1138. doi: 10.1136/bmj.300.6732.1138-a.
3
Raynaud's syndrome.
BMJ. 1990 Apr 14;300(6730):1015-6. doi: 10.1136/bmj.300.6730.1015-b.
4
Once daily felodipine in patients with primary Raynaud's phenomenon.
Eur J Clin Pharmacol. 1991;40(3):313-5. doi: 10.1007/BF00315217.
本文引用的文献
1
Prostaglandin E1 infusions for vascular insufficiency in progressive systemic sclerosis.
Ann Rheum Dis. 1981 Aug;40(4):350-4. doi: 10.1136/ard.40.4.350.
2
Induced vasodilation as treatment for Raynaud's disease.
Ann Intern Med. 1982 Nov;97(5):706-9. doi: 10.7326/0003-4819-97-5-706.
3
Treatment of Raynaud's phenomenon with ketanserin in patients with connective tissue disorders.
Br Med J (Clin Res Ed). 1984 Sep 8;289(6445):577-9. doi: 10.1136/bmj.289.6445.577.
4
Role of cold and emotional stress in Raynaud's disease and scleroderma.
Br Med J (Clin Res Ed). 1983 Nov 19;287(6404):1499-502. doi: 10.1136/bmj.287.6404.1499.
5
Endothelium-dependent relaxation of rabbit aorta. I. Relaxation stimulated by arachidonic acid.
J Pharmacol Exp Ther. 1983 Sep;226(3):790-5.
6
Prostaglandin I3 is formed in vivo in man after dietary eicosapentaenoic acid.
Nature. 1984;307(5947):165-8. doi: 10.1038/307165a0.
7
Thromboxane A3 (TXA3) is formed in human platelets after dietary eicosapentaenoic acid (C20:5 omega 3).
Biochem Biophys Res Commun. 1983 Nov 15;116(3):1091-9. doi: 10.1016/s0006-291x(83)80254-x.
8
Alpha-adrenergic receptors in platelets from patients with Raynaud's syndrome.
Surgery. 1983 Aug;94(2):204-9.
9
Elevated levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma.
Ann Intern Med. 1982 May;96(5):610-3. doi: 10.7326/0003-4819-96-5-610.
10
Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. A double-blind controlled trial.
Lancet. 1983 Feb 12;1(8320):313-5. doi: 10.1016/s0140-6736(83)91624-0.
Zotero 插件